The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast

MARÍA LOURDES LADEHESA PINEDAALEJANDRO ESCUDERO CONTRERASALEJANDRO ESCUDERO CONTRERASE. CLEMENTINA LÓPEZ MEDINAEDUARDO COLLANTES ESTÉVEZROCÍO GUZMÁN RUIZCARLOS PÉREZ SÁNCHEZMARÍA DEL MAR MALAGÓN POYATO2026-01-292026-01-29202210.1111/joim.134472-s2.0-85125447958https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/34639Internal MedicineThe clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilastresearch article